Lewis Joel's Form 4 filing
Galectin Therapeutics Inc (GALT) · filed Dec 26, 2024
- Accession no.
- 0001133416-24-000070
- Filed
- Dec 26, 2024
- Trade date
- Dec 23, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $49.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis JoelCIK 0001725595 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2024 | Common Stock | MOption exerciseAcquired | +56,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units.
Referenced by the price of 1 transaction in Table I.
- F5
Multiple transactions ranging from $0.92 to $0.85 with an average of $0.8859.
Referenced by the price of 1 transaction in Table I.